A Modern Approach to Multiple Sclerosis Trials Applying Innovative Digital Endpoint Solutions
How advances in brain imaging, eCOA solutions and instrumented movement analysis are redefining endpoint strategy in multiple sclerosis drug development
Traditional endpoints in multiple sclerosis trials often lack sensitivity to subtle disease progression and treatment effects. Novel digital endpoints are addressing these limitations by enabling more objective, quantitative assessment of neurological change.
In this webinar, the featured speaker will explore the use of AI-enabled quantitative medical imaging, optimized eCOA solutions and deployment strategies and precision instrumented motion analysis to improve endpoint sensitivity, data quality and decision-making in multiple sclerosis drug development.
Register to learn how a digital endpoint strategy can improve endpoint sensitivity and data quality in multiple sclerosis trials.
Session information:
Time:
- 11:00 a.m. – 12:00 p.m. EDT (NA-East)
- 03:00 p.m. – 04:00 p.m. GMT (UK)
- 04:00 p.m. – 05:00 p.m. CET (EU-Central)
Register for this webinar to learn how a digital endpoint strategy can improve endpoint sensitivity and data quality in multiple sclerosis trials.
In this webinar, attendees will:
- Recognize how traditional MS endpoints can fail to detect meaningful change, and how innovative digital solutions could help detect disease progression and treatment effects earlier
- Learn how AI-enabled quantitative imaging delivers more consistent and objective measurements, reducing variability in imaging-based endpoints
- Understand how to design and optimize eCOA endpoint strategies in MS trials, ensuring that accurate data is collected reliably from patients and clinical raters
- Explore how instrumented gait and balance assessments add objective insight into motor function, complementing clinical and patient-reported measures
Speakers
Todd Rudo, M.D.
EVP, Chief Medical Officer at Clario
Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety.
Dr. Rudo has board certifications in Cardiology, Cardiac Electrophysiology, Nuclear Cardiology, Adult Echocardiography and Internal Medicine. His team provides expert consulting to clients on scientific and regulatory strategy and ensures Clario’s product portfolio is scientifically robust, generating high-quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.
Laura Khurana, MPH
Senior Principal Scientific Advisor, eCOA Science & Consulting at Clario
Laura Khurana is an experienced public health and clinical research professional with a special interest in electronic clinical outcome assessments (eCOAs) for clinical trials. Laura has 17 years of experience in clinical research, initially working in web-based data collection for patient registries and post-approval safety studies. Laura has been at Clario for 10 years, and in her current role as Principal Scientific Advisor, she leads the scientific direction for eCOA services, including designing data collection strategies based on best practices, the literature, patient and site preferences and applicable regulations. She has experience supporting trials across a wide range of clinical indications, including multiple sclerosis, headache and migraine, dermatology and diabetes. Laura earned her MPH from Boston University School of Public Health and her BA from the University of Georgia.
Douglas Arnold, M.D.
Professor, Department of Neurology & Neurosurgery, McGill University
President and CEO, NeuroRx
Senior Advisor at Clario
Dr. Douglas Arnold is a leading figure in multiple sclerosis research and neuroimaging, with a career spanning over three decades at the intersection of academic medicine and clinical innovation. He founded NeuroRx in 2002 to apply cutting-edge imaging science to global clinical trials. NeuroRx is now part of Clario, where Dr. Arnold serves as Senior Advisor.
A Professor at McGill University and a Distinguished James McGill Professor, Dr. Arnold has directed the MRI lab at the McConnell Brain Imaging Center since 1985. His academic credentials include Neurology training at the Montreal Neurological Institute and advanced MRI studies at the University of Oxford.
Dr. Arnold has authored more than 450 peer-reviewed publications and is among the top 1% of most-cited researchers worldwide. His work has significantly influenced MS treatment and imaging standards, with seminal studies featured in The New England Journal of Medicine and The Lancet. He continues to lead initiatives in AI-powered imaging and clinical trial optimization through his roles at NeuroRx and now Clario.
Vrutangkumar V. Shah, Ph.D.
Director of Data Science and Biostatistics, Precision Motion at Clario
Dr. Vrutangkumar V. Shah is a Scientist with over 13 years of experience in clinical research. He is currently working as a Director, Data Science and Biostatistics at Clario, a global data and technology company that supports decentralized clinical trials. He consults with sponsors and CROs in developing the Statistical Analysis Plan (SAP) package for Phase I-IV clinical studies. His expertise includes, but is not limited to, data analytics, biostatistics, machine learning and time-series analysis for developing digital biomarkers for clinical trials.